Betablokátory u kardiovaskulárních onemocnění na počátku 21. století
| Title in English | Beta-blockers in cardiovascular diseases at the beginning of the 21st century |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Popularization text |
| MU Faculty or unit | |
| Citation | |
| Description | Currently, beta blockers (BBs) represent a heterogenous group of drugs with different pharmacokinetic and pharmacodynamic properties and they should not be viewed as a uniform drug class. BBs have protective effects in almost all stages of cardiovascular damage. However, many analyses and pieces of information questioning this – unquestionable so far – role of BB have occurred lately. This review summarizes the new data concerning BBs use in the context hypertension, for secondary prevention of coronary artery disease and arrhythmias, and for treatment of chronic heart failure. BBs offer cardioprotection even to patients with COPD and peripheral artery disease (PAD). It is necessary to choose BBs with high cardiac selectivity and hydrophilic ones showing long enough effect and balanced renal and hepatic clearance. |